Entourage Announces Q4 & Full-Year 2021 Conference Call, Reveals 54% YOY Increase In Revenue

Entourage Health Corp. ENTG ETRGF (FSE:4WE) announced preliminary unaudited total revenues of $54.8 million for the fiscal year ended December 31, 2021, representing an increase of 54% year-over-year.

That’s a record year of sales growth and expanded market share across its adult-use and medical sales channels.

The company plans to file its fourth quarter and full year 2021 financial statements and management’s discussion and analysis by Friday, April 1, 2022.

Entourage will host a conference call at 10 a.m. Eastern time same day to review the results, provide an operational update, discuss recent milestones and provide more details about the financials for the period.

Corporate Update

The company’s board of directors also announced today that George Scorsis has been appointed to the permanent role of CEO, in addition to his role as executive chair of the board.

Serving as the company’s executive chair since December 2019, Scorsis has also held the role of interim chief executive officer of Entourage since January 2021.

“I am thrilled to be leading our talented Entourage team into 2022 with a continued drive for strong execution - focused on revenue growth and financial discipline as we look to achieve our profitability goals by the end of 2022,” Scorsis commented. “Having recently completed the full integration of a newly acquired accretive genetics business, enhanced our cultivation platform and launched some of the most favoured cannabis products in Canada - I’m proud to confirm we closed out a stellar year with expanded market share and a projected $54.8 million in record revenue. We are well positioned for another standout year of growth and I look forward to sharing further updates on our progress.”

Conference Call Details

The conference call will be hosted by Scorsis and Entourage’s CFO, Beth Carreon. Management will be available for questions following opening remarks.

  • Date: Friday, April 1, 2022
  • Time: 10 a.m. Eastern Time
  • Dial-in Number: Canada/USA: 1-800-319-4610. International Toll: 1-604-638-5340
  • Participants, please dial in and ask to join the Entourage call
  • Replay Dial-in: Canada/USA: 1-800-319-6413. International Toll: 1-604-638-9010
  • Replay Access Code: 8486
  • Available after 12:00 p.m. Eastern Time, until May 1, 2022

Photo: Courtesy of Markus Winkler on Unsplash

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: CannabisEarningsNewsPenny StocksMarketsFourth Quarter Earnings
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!
CCC-Oct-24-Banner-1

Click on the image for more info.

Cannabis rescheduling seems to be right around the corner

Want to understand what this means for the future of the industry?

Hear directly for top executives, investors and policymakers at the Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. 

Get your tickets now before prices surge by following this link.